Cytokinetics (CYTK) Non-Current Deffered Revenue (2011 - 2022)

Cytokinetics (CYTK) has reported Non-Current Deffered Revenue for 10 consecutive years, with $87.0 million the latest figure, recorded in Q3 2022.

• In Q3 2022, Non-Current Deffered Revenue changed 0.0% year-over-year to $87.0 million; the TTM figure through Sep 2022 stood at $87.0 million (changed 0.0% YoY), while the FY2021 annual figure was $87.0 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue was little changed at $87.0 million in Q3 2022 per CYTK's latest filing, from $87.0 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $87.0 million in Q4 2020 and bottomed at $87.0 million in Q4 2020.
• Historically, Non-Current Deffered Revenue has averaged $87.0 million across 3 years, with a median of $87.0 million in 2020.
• On a YoY basis, Non-Current Deffered Revenue climbed as much as 0.0% in 2021 and fell as far as 0.0% in 2021.
• Cytokinetics' Non-Current Deffered Revenue stood at $87.0 million in 2020, then changed by 0.0% to $87.0 million in 2021, then changed by 0.0% to $87.0 million in 2022.
• Business Quant data shows CYTK's Non-Current Deffered Revenue at $87.0 million in Q3 2022, $87.0 million in Q1 2022, and $87.0 million in Q4 2021.